May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain ...

Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...

Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Claseprubart granted ...

First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...

Monash University and Seaport Therapeutics have developed a new approach to delivering drug molecules that piggybacks onto natural fat absorption pathways to allow oral delivery of some drugs ...

Performances in N.Y.C. Advertisement Supported by Lise Davidsen’s recital at the Met Opera, Gustavo Dudamel leading “Romeo and Juliet,” and a violinist’s personal program are among our selections.

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Researchers identify bone-forming cells as the driver of scoliosis caused by a genetic disorder, which can be prevented by medications. CHINA, January 14, 2026 ...

Mr. Shinners is a pianist and harpsichordist and hosts the podcast “W.T.F. Bach.” See more of our coverage in your search results.Encuentra más de nuestra cobertura en los resultados de búsqueda. Add ...

Complement-mediated hemolytic uremic syndrome (CM-HUS), commonly referred to as atypical HUS, is a rare thrombotic microangiopathy caused by uncontrolled activation of the alternative complement ...

SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...